Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study - 04/02/21
, Francesca Minoia, MD c, Stefano Aliberti, MD d, e, Giacomo Grasselli, MD e, f, Laura Barbetta, MD g, Valeria Castelli, MD a, Emanuele Palomba, MD a, Laura Alagna, MD a, Andrea Lombardi, MD a, Riccardo Ungaro, MD a, Carlo Agostoni, MD c, h, Marina Baldini, MD i, Francesco Blasi, MD d, e, Matteo Cesari, MD, PhD h, j, Giorgio Costantino, MD f, h, Anna Ludovica Fracanzani, MD e, k, Nicola Montano, MD e, l, Valter Monzani, MD g, Antonio Pesenti, MD e, f, Flora Peyvandi, MD e, m, Marcello Sottocorno, PharmD n, Antonio Muscatello, MD a, Giovanni Filocamo, MD c, Andrea Gori, MD a, e, o, Alessandra Bandera, MD, PhD a, e, o
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Background |
Immunomodulants have been proposed to mitigate severe acute respiratory syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19).
Objective |
We sought to determine efficacy and safety of the association of IL-1 receptor antagonist anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyperinflammation.
Methods |
A secondary analysis of prospective observational cohort studies was carried out at an Italian tertiary health care facility. COVID-19 patients consecutively hospitalized (February 25, 2020, to March 30, 2020) with hyperinflammation (ferritin ≥1000 ng/mL and/or C-reactive protein >10 mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO2 Venturi mask to invasive mechanical ventilation) were evaluated to investigate the effect of high-dose anakinra plus methylprednisolone on survival. Patients were followed from study inclusion to day 28 or death. Crude and adjusted (sex, age, baseline PaO2:FiO2 ratio, Charlson index, baseline mechanical ventilation, hospitalization to inclusion lapse) risks were calculated (Cox proportional regression model).
Results |
A total of 120 COVID-19 patients with hyperinflammation (median age, 62 years; 80.0% males; median PaO2:FiO2 ratio, 151; 32.5% on mechanical ventilation) were evaluated. Of these, 65 were treated with anakinra and methylprednisolone and 55 were untreated historical controls. At 28 days, mortality was 13.9% in treated patients and 35.6% in controls (Kaplan-Meier plots, P = .005). Unadjusted and adjusted risk of death was significantly lower for treated patients compared with controls (hazard ratio, 0.33, 95% CI, 0.15-0.74, P = .007, and HR, 0.18, 95% CI, 0.07-0.50, P = .001, respectively). No significant differences in bloodstream infections or laboratory alterations were registered.
Conclusions |
Treatment with anakinra plus methylprednisolone may be a valid therapeutic option in COVID-19 patients with hyperinflammation and respiratory failure, also on mechanical ventilation. Randomized controlled trials including the use of either agent alone are needed to confirm these results.
Il testo completo di questo articolo è disponibile in PDF.Key words : SARS-CoV-2, COVID-19, hyperinflammation, anti–IL-1, anakinra, corticosteroids, methylprednisolone, immunomodulation, respiratory failure, mechanical ventilation
Abbreviations used : CCI, COVID-19, CRP, MPD, MV, SARS-CoV-2, SOC
Mappa
| Disclosure of potential conflict of interest: F. Minoia and G. Filocamo report consultancy fees from SOBI. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 2
P. 561 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
- Paolo Gisondi, Stefano Piaserico, Luigi Naldi, Paolo Dapavo, Andrea Conti, Piergiorgio Malagoli, Angelo Valerio Marzano, Federico Bardazzi, Massimo Gasperini, Simone Cazzaniga, Antonio Costanzo, collaborators in the studies of COVID-19 pandemic, Lidia Sacchelli, Elena Pezzolo, Francesco Messina, Claudia Lasagni, Laura Bigi, Angelo Cattaneo, Carlo Giovanni Carrera, Luisa Arancio, Simone Ribero, Giulia Rozzo, Giovanni Damiani, Paola Facheris
- Marked changes in innate immunity associated with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells
- Argentina Colmenero-Velázquez, Gloria Esteso, Teresa del Rosal, Ane Calvo Apalategui, Hugh Reyburn, Eduardo López-Granados
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.